Inside Sionna’s Bid To Normalize CFTR Function

Send us Fan Mail Two leaders from Sionna Therapeutics walk through a 15‑year journey from Genzyme science to a public company advancing NBD1‑targeted therapies in cystic fibrosis. We examine why most patients still fall short of normal CFTR, how a predictive assay de‑risks choices, and what it takes to finance, hire, and execute with patients as the North Star. Visit: sionnatx.com Visit Labtolives.com Do you want to try the quiz from this episode? Find the link on our LinkedIn profile: https://www.linkedin.com/company/labtolives/ Would you like to join the show as a guest or collaborator? Find out how on our website: https://www.labtolives.com/ Support the show ________ Reach out to Ivanna Rosendal Join the conversation on our LinkedIn page Visit www.labtolives.com Hosts Alexander Booth aka the MedTech Guy Dimitri Borisevich aka the start-up Guy Ivanna Rosendal aka the R&D pharma Gal